Last reviewed · How we verify

BIO101 — Competitive Intelligence Brief

BIO101 (BIO101) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SARM1 inhibitor. Area: Neurology.

phase 2 SARM1 inhibitor SARM1 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

BIO101 (BIO101) — Biophytis. BIO101 is a small molecule targeting the SARM1 protein to prevent mitochondrial dysfunction.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BIO101 TARGET BIO101 Biophytis phase 2 SARM1 inhibitor SARM1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SARM1 inhibitor class)

  1. Biophytis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BIO101 — Competitive Intelligence Brief. https://druglandscape.com/ci/bio101. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: